ZyVersa is advancing a therapeutic development pipeline with multiple programs focused on kidney and inflammatory diseases.
Lead indications include VAR 200 for FSGS and IC 100 for cardiometabolic conditions.
Raised $2.05 million in Q3-2025 and $4.05 million year-to-date.
Financial Results
Cash on hand: $0.5 million; Need additional financing for operations and pipeline development.
Research & Development
R&D expenses decreased by 16.3% due to fewer consultants; General & administrative expenses decreased by 5.1%.
Pre-tax & Net Losses
Pre-tax losses increased to $20.7 million; Net losses increased to $19.8 million primarily due to impairment charges.
- The financial results indicate a need for additional financing to support ongoing operations and pipeline development.
- Significant increases in losses compared to the previous year demonstrate challenges in sustaining financial stability.
ZyVersa faces financial challenges requiring additional funding for operations and development. The increased losses highlight the importance of strategic financial management and investment decisions.